COMMERCIALIZATION
World-changing solutions.
Amplified impact.
SRI investment, innovation, partnership, and product professionals work with federal and commercial clients to inform and accelerate deep-tech innovation through commercial R&D, IP licensing, startup support, and so much more.
Innovating in
13,000+patents filed
100+active licenses
$4B+federal funding(past 10 years)
30+startups in portfolio
“You may know SRI for its unparalleled research legacy in Silicon Valley and throughout the U.S. But how we take this bold portfolio of innovation to market will define the impact SRI will have in the next half a century.”
Suresh SunderrajanPresident, Commercialization
How we work
Here’s how we work with visionaries to bring ideas to fruition—and to market.
Real-world impact
-
SRI earns FDA Orphan Drug Designation for pancreatic cancer
The designation accelerates clinical development of SRI’s TALL® immunotherapy and brings more affordable therapies to market faster. SRI’s Targeted Antigen Loaded Liposomes (TALL) — a treatment that expands the benefits of immunotherapy such as check-point inhibitors — has been granted Orphan Drug Designation (ODD) for pancreatic ductal adenocarcinoma (PDAC) by the U.S. Federal Drug Administration (FDA). As a result,…
-
Podcast: A reading intervention for struggling adolescent students
The SERP Institute’s Margaret Troyer and Kala Jones discuss a research-based reading program that helps older students turn the page.
-
SRI researchers watched over 1000 YouTube videos for kids, and this is what they learned
Most YouTube videos intended to teach early literacy and math don’t use characters or narratives, according to recent SRI research.